Diabetes and the treatment of ischemic stroke

Enming J Su; Daniel A Lawrence

doi:10.1016/j.jdiacomp.2022.108318

Diabetes and the treatment of ischemic stroke

J Diabetes Complications. 2022 Nov;36(11):108318. doi: 10.1016/j.jdiacomp.2022.108318. Epub 2022 Oct 6.

Authors

Enming J Su¹, Daniel A Lawrence²

Affiliations

¹ Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
² Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA. Electronic address: dlawrenc@umich.edu.

PMID: 36228562
DOI: 10.1016/j.jdiacomp.2022.108318

Abstract

This white paper examines the current challenges for treating ischemic stroke in diabetic patients. The need for a greater understanding of the mechanisms that underlie the relationship between diabetes and the cerebral vascular responses to ischemia is discussed. The critical need to improve the efficacy and safety of thrombolysis is addressed, as is the need for a better characterization the off-target actions of tPA, the only currently approved thrombolytic for the treatment of ischemic stroke.

Keywords: Diabetes; Stroke; Thrombolysis; Tissue plasminogen activator.

Publication types

Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Brain Ischemia* / complications
Brain Ischemia* / therapy
Diabetes Mellitus* / epidemiology
Diabetes Mellitus* / therapy
Humans
Ischemic Stroke*
Stroke* / complications
Stroke* / therapy
Tissue Plasminogen Activator
Treatment Outcome

Substances

Tissue Plasminogen Activator

Grants and funding

R01 HL055374/HL/NHLBI NIH HHS/United States